Recent clinical observations demonstrate adiponectin (APN), an adipocytokine with potent cardioprotective actions, is significantly reduced following myocardial ischemia/reperfusion (MI/R). However, mechanisms responsible for MI/ R-induced hypoadiponectinemia remain incompletely understood. Adult male mice were subjected to 30-min MI followed by varying reperfusion periods. Adipocyte APN mRNA and protein expression and plasma APN and TNF␣ concentrations were determined. APN expression/production began to decline 3 h after reperfusion (reaching nadir 12 h after reperfusion), returning to control levels 7 days after reperfusion. Plasma TNF␣ levels began to increase 1 h after reperfusion, peaking at 3 h and returning to control levels 24 h after reperfusion. TNF␣ knockout significantly increased plasma APN levels 12 h after reperfusion but failed to improve APN expression/ production 72 h after reperfusion. In contrast, TNF receptor-1 (TNFR1) knockout significantly restored APN expression 12 and 72 h after reperfusion, suggesting that other TNFR1 binding cytokines contribute to MI/R-induced APN suppression. Among many cytokines increased after MI/R, lymphotoxin-␣ (LT␣) was the only cytokine remaining elevated 24 -72 h after reperfusion. LT␣ knockout did not augment APN levels 12 h post-reperfusion, but did so by 72 h. Finally, in vitro treatment of adipocytes with TNF␣ and LT␣ at concentrations seen in MI/R plasma additively inhibited APN expression/production in TNFR1-dependent fashion. Our study demonstrates for the first time that LT␣ is a novel suppressor of APN expression and contributes to the sustained hypoadiponectinemia following MI/R. Combining anti-TNF␣ with anti-LT␣ strategies may achieve the best effects restoring APN in MI/R patients.
EARLY REPERFUSION AFTER CORONARY OCCLUSION remains the most effective means of limiting ischemic myocardial injury. However, evidence from animal studies, as well as clinical observations, demonstrates that reperfusion itself may cause additional cell death, defined as "reperfusion injury" (3) . Strong epidemiological evidence suggests type 2 diabetes not only causes coronary vascular injury, thereby increasing ischemic heart disease prevalence, but also exacerbates cardiac injury after ischemia/reperfusion insult in these patients (2, 8, 15) . Clarifying the molecular link between type 2 diabetes and cardiovascular injury may therefore help identify novel effective therapeutic interventions attenuating postischemic myocardial injury, reducing myocardial ischemic morbidity, and ultimately decreasing diabetic mortality.
Adiponectin (APN) is a protein hormone primarily produced by adipocytes (18) . In contrast to the majority of adipokines (e.g., TNF␣), which are significantly increased in diabetic patients and proinflammatory, APN is markedly reduced in diabetic patients and is potently protective of the vasculature (16, 25, 27) . Plasma APN levels significantly decrease after tissue injury, such as acute lung injury caused by ovalbumin challenge (26) . Numerous epidemiological studies reveal the association between hypoadiponectinemia and increased cardiovascular disease risk in obesity and diabetes (4, 7, 13, 32) . Additionally, recent clinical observations demonstrate post-MI plasma APN levels correlate positively with myocardial salvage index and ejection fraction recovery (23) . Persistent plasma hypoadiponectinemia post myocardial infarction is predictive of future adverse cardiac events (1) . However, the molecular mechanisms responsible for post-MI APN suppression remain unidentified.
TNF␣ is a well-recognized prooxidative cytokine belonging to the same structural family (C1q/TNF superfamily) as APN. Despite their conformational similarities, these two cytokines exert opposite biological effects and reciprocally regulate each other's expression and production. Clinical observations demonstrate that elevated plasma TNF␣ is associated with low plasma APN levels (11) , and anti-TNF␣ treatment increases plasma APN (12) . Although it is well known that TNF␣ significantly increases after MI/R, and in vitro experiments demonstrate TNF␣ inhibits APN mRNA expression (5), whether augmented TNF␣ post-MI is solely responsible for hypoadiponectinemia has not been previously investigated.
Lymphotoxin-␣ (LT␣, also known as TNF␤) is a member of the TNF family, synthesized primarily by activated T and B lymphocytes (17) . Previous studies demonstrate that LT␣ shares the same membrane receptors as TNF␣, exerting its biological effect largely via TNF receptor 1 (TNFR1) and TNFR2 activation (17) . However, the effect of LT␣ on APN expression has never been previously investigated.
Therefore, the aim of the present study was to determine the mechanisms responsible for post-MI hypoadiponectinemia, and to assess the role of TNF␣ and other cytokines in the regulation of APN after MI. Adipocyte cell culture. 3T3-L1 preadipocytes were grown to confluence in DMEM containing 10% FBS and penicillin-streptomycin (100 U/ml) at 37°C in a humidified 5% CO2 atmosphere. Cells were induced to adipocyte differentiation 24 h after confluence by changing the medium to DMEM supplemented with 10% FBS, 5 g/ml insulin, 0.5 mM 3-isobutylmethylxanthine, and 0.25 mM dexamethasone sodium phosphate for 48 h. Thereafter, cells were grown in medium containing only insulin and refreshed subsequently every 48 h. Cells were treated with TNF␣ and LT␣ (100 pg/ml) alone or in combination 9 -10 days after differentiation (defined as Ͼ90% adipocyte phenotype). The effect of TNF␣ or LT␣ on APN mRNA expression (PCR), protein expression (Western), and secretion (APN concentration in culture medium) was determined 3-72 h after treatment. To knock down TNFR1 protein expression, 50 nM TNFR1 siRNA or scramble siRNA (Santa Cruz Biotechnology) was transfected into differentiated 3T3-L1 cells (6 days after differentiation induction) via Lipofectamin 2000 reagent (Invitrogen, Grand Island, NY) per manufacturer's instructions. After transfection (72 h), the efficiency of siRNAmediated TNFR1 knockdown was determined by Western blot. Cells were then treated with TNF␣/LT␣ as described above.
MATERIALS AND METHODS

Animals
Western blot analysis. Proteins were separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membranes, and incubated with primary antibodies (anti-APN and anti-tubulin; Cell Signaling Technology, Danvers, MA) followed by horseradish peroxidase-conjugated secondary antibody (Abcam, Cambridge, MA). The blot was developed with a Supersignal Chemiluminescence detection kit (Pierce, Rockford, IL) and observed with a Kodak Image Station 4000R Pro (Rochester, NY).
Statistical analysis. All values in the text and figures are presented as means Ϯ SE of n independent experiments. Data (except Western blot density) were subjected to one-way ANOVA followed by Bonferoni correction for post hoc test. Western blot densities were analyzed with the Kruskal-Wallis test followed by Dunn's post hoc test. Probabilities of 0.05 or less were considered statistically significant.
RESULTS
MI/R inhibits APN expression/production. APN mRNA expression began to decline as early as 3 h after reperfusion, reaching nadir 12 h after reperfusion (72% reduction vs. sham MI/R group). APN mRNA expression slightly increased 24 and 48 h post-reperfusion and then modestly declined again 72 h after reperfusion. After 7 days of reperfusion, APN recovered to levels statistically similar to those of control (Fig. 1A) . The plasma APN level trend was similar to adipocyte APN mRNA expression, except that plasma APN protein nadir occurred 24 h after reperfusion (Fig. 1B) .
Different effect of TNF␣ and TNFR1 knockout on post-MI/R APN suppression. It is well recognized that MI/R stimulates TNF␣ production. Moreover, previous in vitro studies have demonstrated that TNF␣ inhibits APN expression. To determine the causative role of TNF␣ in post-MI/R hypoadiponectinemia, we determined the effect of TNF␣ knockout on post-MI/R APN expression. Adipocyte TNF␣ expression was slightly increased before MI/R in TNF␣ knockout mice ( Fig. 2A) . TNF␣ knockout almost completely abolished the inhibitory effect of MI/R on APN expression 12 h post-MI/R (P Ͻ 0.01). However, TNF␣ knockout had no effect on APN expression 72 h after MI/R. TNF␣ achieves its biological function via activation of two cell membrane receptors, TNFR1 and TNFR2. Our recent in vitro experimental results demonstrate the inhibitory effect of TNF␣ on APN expression is mediated by TNFR1. TNFR1 knockout mice were employed to determine whether TNFR1 knockout might similarly affect in vivo APN expression. TNFR1 knockout had a similar effect on APN expression as TNF␣ knockout before and 12 h after MI/R (Fig. 2B) . Although TNF␣ knockout failed to restore APN expression 72 h after reperfusion, TNFR1 knockout markedly reversed the inhibitory effect of MI/R on APN expression 72 h after reperfusion. These results suggest that, although TNF␣ overproduction is largely responsible for the inhibitory effect of MI/R on APN expression at an early time point (i.e., 12 h), other cytokines capable of binding with TNFR1 are responsible for the inhibitory effect of MI/R on APN expression at a late time point (i.e., 72 h).
To identify novel molecules inhibiting APN expression, plasma concentrations of TNF␣, IL-1␤, IL-6, IL-18, TGF␤, and LT␣ were determined throughout the MI/R period. Among the cytokines investigated, LT␣ was an attractive candidate for the following three reasons. First, plasma TNF␣ levels rapidly increase after reperfusion, returning to control levels 24 h after reperfusion (Fig. 3A) , suggesting that plasma TNF␣ may not be responsible for late-phase (i.e., 72 h after reperfusion) APN suppression. Second, although multiple cytokines increased after MI/R (data not shown), LT␣ was the only protein that remained elevated 48 -72 h after reperfusion (Fig. 3B) , a time point during the second phase of APN suppression, not reversed by TNF␣ knockout. Third, previous studies have demonstrated that LT␣ shares the same receptors with TNF␣. To obtain direct evidence supporting the role of LT␣ in late-phase APN suppression after MI/R, we determined the effect of LT␣ knockout on APN expression. LT␣ knockout had no effect on APN expression before MI or 12 h after reperfusion (Fig. 3C) . However, APN expression levels were significantly increased 72 h after reperfusion. Taken together, these results suggest that LT␣ may be responsible for late-phase APN suppression after MI/R. Additive effect of TNF␣ and LT␣ on adipocyte APN expression. The aforementioned in vivo experimental results strongly suggest that TNF␣ and LT␣ are two cytokines inhibiting APN expression after MI/R. We next performed in vitro experiments to determine whether these two cytokines might additively inhibit adipocyte APN expression. Consistent with previous reports, TNF␣ treatment significantly inhibited APN mRNA expression (Fig. 4A) , protein expression (Fig. 4B) , and APN secretion (Fig. 4C) . Treatment of adipocytes with LT␣ at concentrations observed in plasma after MI/R significantly inhibited APN mRNA expression (Fig. 5A), protein expression (Fig. 5B) , and APN secretion (Fig.  5C) . Finally, treatment with TNF␣ and LT␣ additively inhibited APN expression and production (Fig. 6, A-C) .
TNFR1 knockout significantly attenuated TNF␣/LT␣ inhibition of APN expression. In a final attempt to determine the regulatory role of LT␣ in adipocyte APN expression, we determined the effect of siRNA-mediated TNFR1 expression knockdown on TNF␣/LT␣-mediated inhibition of APN expression. siRNA against TNFR1 effectively inhibited adipocyte TNFR1 expression (79 Ϯ 4.9%). More importantly, TNFR1 downregulation markedly attenuated the inhibitory effect of TNF␣/LT␣ on adipocyte APN expression (Fig. 7A) and production (Fig. 7B) .
DISCUSSION
Substantial evidence supports reciprocal inhibitory regulation between TNF␣ and APN (14) . Clinical observations demonstrate that elevated plasma TNF␣ is associated with low plasma APN levels (11) and that anti-TNF␣ treatment increases plasma APN (12) . In vitro experiments demonstrate that TNF␣ markedly inhibits APN mRNA expression and secretion in both dose-and time-dependent manners (5) . TNF␣ also decreases rosiglitazone-stimulated APN promoter activity in adipocytes (31) . Several mechanisms have been proposed to explain the inhibitory effect of TNF␣ on APN expression (14) . First, TNF␣ decreases APN production by suppressing the expression of several factors promoting APN specifically, such as PPAR␥, C/EBP, SREBP, DsbA-L, and retinoid X receptor-␣. Second, TNF␣ induces inhibitory transcription factor IGFBP3, which suppresses APN transcription and induces insulin resistance. Finally, TNF␣ inhibits APN expression by activating JNK and NF-B systems. Conversely, APN significantly inhibits TNF␣ expression/production (19) . Early studies demonstrate significantly increased TNF␣ levels in APN knockout mice (30) . Recent studies demonstrate that APN inhibits TNF␣ production via multiple mechanisms, including inhibiting NF-B activation, promoting anti-inflammatory cytokine production, and activating the cyclooxygenase-2/prostaglandin E 2 pathway (6, 24) . Utilizing a TNF␣ knockout approach, we provide the first direct in vivo evidence that TNF␣ overproduction is responsible for hypoadiponectinemia occurring early after reperfusion. Although other proinflammatory cytokines (such as IL-6 and IL-18) have been previously reported to inhibit APN expression in cultured adipocytes (14), the current study does not support the major role of such cytokines in post-MI/R hypoadiponectinemia, as TNF␣ knockout recovered greater than 80% APN expression 12 h after reperfusion. A likely explanation for the discrepancy between our current in vivo experimental results and previously reported in vitro results is that plasma IL-6 and IL-18 levels were only slightly elevated and transient after in vivo reperfusion, whereas prolonged high concentrations of IL-6 and IL-18 were utilized in previous culture cell studies (14) . This possibility is supported by our data demonstrating that the inhibitory effect of MI/R on APN expression/production is less than previously reported from in vitro cell culture studies by TNF␣ (91-97% reduction in APN mRNA expression after 1-3 days of TNF␣ incubation) (5) . Most in vitro cell culture studies employed high TNF␣ concentrations (in the ng/ml range), with nearly complete inhibition of resultant APN expression. In our study, although in vivo MI/R markedly increased plasma TNF␣ levels compared with controls, such TNF␣ levels in MI/R animals (at the very maximum) remained in the picogram per milliliter range.
LT␣, a member of the TNF family, is synthesized primarily by activated T and B lymphocytes (17) . It is expressed in either a secreted or a membrane-bound form exhibiting different affinity for various receptors. The secreted soluble homotrimeric form binds to the TNFR1 and TNFR2 receptors with high affinity, whereas the transmembrane heterotrimeric form (one LT␣ plus two LT␤) binds with high specificity to the LT␤ receptor (LT␤R). LT␣ mediates a large variety of inflammatory, immunostimulatory, and antiviral responses, affects cell death or differentiation, and provides an important communicative link between lymphocytes and stromal cells (17) . Several genetic and clinical studies have demonstrated that variations in the gene encoding LT␣ affecting its expression and biological function contribute to the risk of coronary artery disease, myocardial infarction, aortic aneurysm formation, and cerebral infarction (10, 22) . Recent clinical studies demonstrate that LT␣ gene variability is also associated with features of the metabolic syndrome, including increased level of C-reactive protein, hyperinsulinemia, and dyslipidemia (9) .
Considerable indirect evidence suggests the interplay between LT␣ and APN. LT␣ is a potent proinflammatory factor, whereas APN is a well-recognized anti-inflammatory molecule. Whereas APN knockout increases atherosclerosis formation (20) , loss of LT␣ reduces lesion size by 62% (21) . Moreover, LT␣ gene variability is associated with hypoadiponectinemia (9) . Finally, a recent study demonstrates that APN inhibits lymphotoxin-induced adhesion molecule expression in human umbilical vein endothelial cells via inhibition of NF-B activation (29) . Utilizing LT␣ knockout mice and combining both in vivo and in vitro approaches, we provide the first direct evidence that LT␣ is a novel APN expression suppressor and contributes to hypoadiponectinemia occurring late after reperfusion. These results also suggest that the previously reported proatherosclerotic role of LT␣ may be mediated by APN inhibition. Experiments obtaining direct evidence supporting this interesting hypothesis are currently in progress.
In summary, our current study has provided direct evidence that TNF␣ overproduction immediately after MI/R inhibits cardioprotective APN expression/production and is responsible for the hypoadiponectinemia during the early phase of reperfusion. In contrast, increased LT␣ production occurring after 48-h reperfusion is a novel suppressor of APN expression/production during the late phase of reperfusion. Moreover, TNFR1 knockout blocked the suppressive effect of both TNF␣ and LT␣ on APN. These experimental results suggest that simultaneous inhibition of TNF␣ and LT␣, or targeted inhibition of TNFR1 function, may be novel approaches restoring APN expression/production in MI/R patients.
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